VIENNA, Va. and MCLEAN, Va., May 22, 2014 (GLOBE NEWSWIRE) -- Personalized Cancer Therapy, Inc. (d.b.a. Perthera), a precision cancer therapy firm, today announces an upcoming webinar discussing "The Promise of Precision Medicine." Hosted by Chris4Life Colon Cancer Foundation and COLONTOWN, a national non-profit advocacy organization. The educational webinar will be held on Thursday, June 12 from 7:00-8:00 p.m. EST.
During the webinar, Michael Pishvaian, MD, PhD, director of the Phase I Clinical Trial Program at the Lombardi Comprehensive Cancer Center, Georgetown University and chief medical officer for Perthera, will detail the latest scientific advances that enable a broad-based molecular analysis of cancer tumors to help the patient and their oncologist understand which specific drug or treatment combination would work best for them.
"As cancers are becoming defined more by the driving molecular abnormalities and less by the organ in which the cancer originated, a personalized approach to the analysis and treatment of cancer is helping oncologists provide the most expedient diagnosis and the highest quality treatment during these critical, life-changing periods," says Dr. Pishvaian.
Colon cancer patients, family members, oncologists, members of the scientific community and anyone with an interest in precision medicine's role in cancer treatment are encouraged to attend. To register for the event visit the Chris4Life registration page.
Dr. Pishvaian is a gastro-intestinal oncologist focused on translational cancer care. His background as an MD and a PhD has put him in a unique position to understand the basic science of targeted therapies in oncology, while providing him with the training as a compassionate clinical oncologist. His area of focus is the development of rational combinations of novel, targeted anti-cancer agents, with a particular emphasis on pancreatic cancer, and refractory colorectal cancer. Dr. Pishvaian is Principal Investigator on several clinical trials, including Phase I trials, and Phase II trials for patients with colorectal and pancreatic cancer. Each of Dr. Pishvaian's trials are heavily focused on the acquisition and analysis of patient tumor biopsies to identify molecular markers that are predictive of response to therapy.
Perthera is a committed Advocacy Organization to Chris4Life as the foundation continues its efforts to increase awareness of colon cancer, improve survival and outcomes and to understand how to treat patients more effectively with better therapies. Chris4Life recognizes the value of personalized medicine and Perthera's role in providing the right patient with the right treatment.
About Chris4Life Colon Cancer Foundation
The principal goal of Chris4Life Colon Cancer Foundation is to permanently eliminate the threat of colon cancer through discovery of a cure. As long as people are dying from this disease, we will be at the front lines of the fight. To this end, we will fund cutting edge research so that the brightest minds and best institutions are empowered to cure colon cancer for good. Until then, Chris4Life Colon Cancer Foundation is committed to significantly improving the treatment experience for patients and caregivers through its partnership with COLONTOWN, and to dramatically raise awareness about colorectal cancer in general. Chris4Life will utilize health and wellness as a means of integrating the mind, body and spirit in our approach. Working together we will build a culture of care and foster relationships with research institutions, advocacy groups, the health care community, and the general public. Chris4Life four core values are Compassion, Empowerment, Perseverance, and Life.
Based in McLean, Virginia, Personalized Cancer Therapy, Inc. (d.b.a. Perthera) offers a concierge service that helps oncologists identify the best treatment options for patients employing chemotherapy to fight cancer. The company uses targeted molecular testing and its proprietary Perthera Expert Oncology technology of molecular cancer profiles to recommend the latest treatment therapies individualized for each patient and his or her physician.